Beijing’s Yisheng Biopharma reported that its first-in-class immuno-oncology candidate, YS-ON-001, showed strong anti-tumor efficacy in pre-clinical tests, though Yisheng did not release specific data. Unlike most immuno-oncology candidates, YS-ON-001 has neither a PD-1 or CAR-T mechanism. The company said YS-ON-001 out-performed PD-1 candidates in one-on-one tests, but when combined with a PD-1 candidate, the efficacy of YS-ON-001 was increased in several animal models of solid tumor cancers, including triple negative breast cancer. YS-ON-001, a biologic drug, promotes several immune reactions including Th1-based inflammation.
Source: China Biotoday
